NUCYNTA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NUCYNTA (NUCYNTA).
Tapentadol is a centrally acting analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition.
| Metabolism | Tapentadol is primarily metabolized via glucuronidation (UGT1A9 and UGT2B7) and to a lesser extent by CYP2C9 and CYP2D6; no active metabolites. |
| Excretion | Primarily renal excretion (approximately 95% of the dose is excreted in urine as tapentadol and its conjugates; <1% excreted unchanged in feces). |
| Half-life | Terminal elimination half-life is approximately 4 hours (range 3-5 hours); no significant accumulation with repeated dosing at recommended intervals. |
| Protein binding | Approximately 20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Volume of distribution is approximately 540 L (or 7.7 L/kg for a 70 kg individual), indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 32% (due to extensive first-pass metabolism; absolute bioavailability is 32% for tapentadol HCl). |
| Onset of Action | Oral: Analgesic effect begins within 30-60 minutes; peak effect occurs at 1-2 hours. |
| Duration of Action | Duration of analgesia is approximately 4-6 hours with immediate-release formulation; dose interval is every 4-6 hours as needed. |
50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg/day.
| Dosage form | SOLUTION |
| Renal impairment | For GFR 30-59 mL/min: 50 mg every 6 hours; maximum 300 mg/day. For GFR 15-29 mL/min: 50 mg every 8 hours; maximum 200 mg/day. For GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment needed. Child-Pugh B: 50 mg every 8 hours; maximum 300 mg/day. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in patients under 18 years of age. |
| Geriatric use | For patients over 65 years, consider starting at 50 mg every 6 hours; maximum 300 mg/day due to potential renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NUCYNTA (NUCYNTA).
| Breastfeeding | Minimally excreted in breast milk; M/P ratio not established. Limited data suggest low relative infant dose. Caution with prolonged use; monitor infant for drowsiness and feeding difficulties. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may lead to neonatal opioid withdrawal syndrome (NOWS) with prolonged exposure. Avoid in third trimester near term due to risk of respiratory depression in the neonate. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse, which can lead to overdose and death. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.
| Serious Effects |
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction; hypersensitivity to tapentadol or any component of the formulation.
| Precautions | Serotonin syndrome with concurrent use of serotonergic drugs; risk of seizures in patients with seizure disorders; respiratory depression; risk of adrenal insufficiency; severe hypotension; risk of misuse and abuse. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal respiratory status, sedation, and bowel function; fetal heart rate monitoring during labor; neonatal assessment for signs of opioid withdrawal or respiratory depression at birth. |
| Fertility Effects | No clinical data on fertility effects in humans; animal studies indicate no significant impact on reproductive parameters at therapeutic doses. |